论文部分内容阅读
目的:探讨芪参益肺汤防治肺癌放疗所致放射性肺炎的疗效。方法:将110例接受放疗的肺癌患者按数字随机表法分为2组,每组55例,两组均给予肺癌三维适型放疗,治疗组同时给予芪参益肺汤口服,连续服用8周。比较两组放射性肺炎的发生率、发生时间、发生时接受的放射线剂量和症状严重程度,并比较两组放疗前后肺活量(VC)、用力肺活量(FVC)、第1秒呼气容积(FEV1)和血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、转化生长因子β1(TGF-β1)水平。结果:治疗组临床有效率和疾病控制率与对照组差异无统计学意义;对照组放射性肺炎发生率高于治疗组,发生时间和发生时接受的放射线剂量均少于治疗组;治疗组症状严重程度显著低于对照组(P<0.05);治疗组VC、FVC、FEV1均高于对照组(P<0.05,P<0.01);血清IL-6、TNF-α、TGF-β1水平均低于对照组(P<0.01)。结论:芪参益肺汤可有效保护肺功能,减少放射性肺炎发生率,降低肺损伤症状,有利于保障肺癌患者治疗方案的顺利进行。
Objective: To investigate the effect of Qishen Yifei Decoction in preventing and treating radiation pneumonitis caused by radiotherapy of lung cancer. Methods: One hundred and ten lung cancer patients undergoing radiotherapy were divided into two groups according to the random number table method, 55 cases in each group. Both groups were given three-dimensional radiation therapy of lung cancer. The treatment group was treated with Qishen Yifei decoction orally for 8 weeks . The incidence of radiation pneumonitis, the time of onset, the dose of radiation and the severity of symptoms were compared between the two groups. The vital capacity (VVC), forced vital capacity (FVC), first-second expiratory volume (FEV1) Serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) Results: The clinical effective rate and disease control rate in the treatment group were not significantly different from those in the control group. The incidence of radiation pneumonitis in the control group was higher than that in the treatment group, and the radiation dose was less than that in the treatment group at the time of onset and occurrence. The levels of VC, FVC and FEV1 in the treatment group were significantly higher than those in the control group (P <0.05, P <0.01), and the levels of IL-6, TNF-α and TGF- Control group (P <0.01). Conclusion: Qishen Yifei Decoction can effectively protect the lung function, reduce the incidence of radiation pneumonitis and reduce the symptoms of lung injury, which is beneficial to ensure the smooth progress of the treatment of lung cancer patients.